Provided by Tiger Fintech (Singapore) Pte. Ltd.

uniQure NV

13.15
+0.36002.81%
Volume:1.77M
Turnover:23.00M
Market Cap:719.69M
PE:-3.01
High:13.42
Open:12.76
Low:12.55
Close:12.79
Loading ...

uniQure Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
27 Jan

uniQure Price Target Maintained With a $24.00/Share by RBC Capital

Dow Jones
·
22 Jan

uniQure (QURE) Gets a Buy from Wells Fargo

TIPRANKS
·
16 Jan

Here’s Why uniQure N.V. (QURE) Is Skyrocketing

Insider Monkey
·
14 Jan

Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025?

Insider Monkey
·
12 Jan

uniQure call volume above normal and directionally bullish

TIPRANKS
·
09 Jan

uniQure Prices $75 Million Public Offering; Shares Fall

MT Newswires Live
·
08 Jan

UniQure Announces Pricing Of Its Public Offering

Reuters
·
08 Jan

uniQure Launches Public Offering of Shares, Pre-Funded Warrants

MT Newswires Live
·
08 Jan

UniQure Files Mixed Shelf; Shares Fall After Hours

MT Newswires Live
·
08 Jan

uniQure announces ordinary share, warrant offering, no amount given

TIPRANKS
·
08 Jan

uniQure Announces Proposed Public Offering

GlobeNewswire
·
08 Jan

uniQure files automatic mixed securities shelf

TIPRANKS
·
08 Jan

RBC Raises Price Target on uniQure to $24 From $20, Keeps Outperform, Speculative Risk

MT Newswires Live
·
07 Jan

Mizuho Securities Reaffirms Their Hold Rating on uniQure (QURE)

TIPRANKS
·
21 Dec 2024

uniQure call volume above normal and directionally bullish

TIPRANKS
·
20 Dec 2024

Uniqure Nv : Mizuho Raises Target Price to $20 From $7

THOMSON REUTERS
·
19 Dec 2024

uniQure price target raised to $32 from $12 at Stifel

TipRanks
·
17 Dec 2024

uniQure Is Maintained at Outperform by Leerink Partners

Dow Jones
·
12 Dec 2024

Stock Track | uniQure Soars 5.16% on FDA Alignment for Accelerated Approval Pathway of Huntington's Disease Gene Therapy

Stock Track
·
12 Dec 2024